Cargando…
P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430533/ http://dx.doi.org/10.1097/01.HS9.0000847352.16311.ea |
| _version_ | 1784779796808466432 |
|---|---|
| author | Joffe, E. Nowakowski, G. Tun, H. Rosenthal, A. Lunning, M. Ramchandren, R. Li, C.-C. Zhou, L. Martinez, E. von Roemeling, R. Earhart, R. McMahon, M. Isufi, I. Leslie, L. |
| author_facet | Joffe, E. Nowakowski, G. Tun, H. Rosenthal, A. Lunning, M. Ramchandren, R. Li, C.-C. Zhou, L. Martinez, E. von Roemeling, R. Earhart, R. McMahon, M. Isufi, I. Leslie, L. |
| author_sort | Joffe, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430533 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94305332022-08-31 P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Joffe, E. Nowakowski, G. Tun, H. Rosenthal, A. Lunning, M. Ramchandren, R. Li, C.-C. Zhou, L. Martinez, E. von Roemeling, R. Earhart, R. McMahon, M. Isufi, I. Leslie, L. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430533/ http://dx.doi.org/10.1097/01.HS9.0000847352.16311.ea Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Joffe, E. Nowakowski, G. Tun, H. Rosenthal, A. Lunning, M. Ramchandren, R. Li, C.-C. Zhou, L. Martinez, E. von Roemeling, R. Earhart, R. McMahon, M. Isufi, I. Leslie, L. P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_full | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_fullStr | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_full_unstemmed | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_short | P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES |
| title_sort | p1121: takeaim lymphoma- an open-label, dose escalation and expansion trial of emavusertib (ca-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430533/ http://dx.doi.org/10.1097/01.HS9.0000847352.16311.ea |
| work_keys_str_mv | AT joffee p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT nowakowskig p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT tunh p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT rosenthala p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT lunningm p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT ramchandrenr p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT licc p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT zhoul p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT martineze p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT vonroemelingr p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT earhartr p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT mcmahonm p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT isufii p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies AT lesliel p1121takeaimlymphomaanopenlabeldoseescalationandexpansiontrialofemavusertibca4948incombinationwithibrutinibinpatientswithrelapsedorrefractoryhematologicmalignancies |